SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Genmab Reports Phase 2 Data Showing Median Overall Survival Above Two Years

Genmab said updated Phase 2 results showed median overall survival of more than two years for petosemtamab plus pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma.

GMAB

Related stories